← back to search

Joel M. Neutel

New York University · US
Area of research
Cardiology and Cardiovascular Medicine · Endocrinology, Diabetes and Metabolism
Research interest
Research focused on Evolocumab and Ritonavir, with related work in Blood pressure, Amlodipine, Ezetimibe. Notable publications include 'Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia', 'Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of COVID ‐19, in Subjects With Renal Impairment', and 'Single‐Pill Combination of Telmisartan/Amlodipine in Patients With Severe Hypertension: Results From the TEAMSTA Severe HTN Study'.
h-index
citations
634
works
5
NIH funding
primary concept
email

Recent publications

Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of <scp>COVID</scp>‐19, in Subjects With Renal Impairment
Clinical Pharmacology & Therapeutics 2022cited by 66position: middledoi
Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia
JAMA 2014cited by 499position: middledoi
Rationale and Design of <scp>LAPLACE</scp>‐2: A Phase 3, Randomized, Double‐Blind, Placebo‐ and Ezetimibe‐Controlled Trial Evaluating the Efficacy and Safety of Evolocumab in Subjects With Hypercholesterolemia on Background Statin Therapy
Clinical Cardiology 2014cited by 15position: middledoi
Single‐Pill Combination of Telmisartan/Amlodipine in Patients With Severe Hypertension: Results From the TEAMSTA Severe HTN Study
Journal of Clinical Hypertension 2012cited by 33position: firstdoi
Single-Pill Combination of Telmisartan/Amlodipine Versus Amlodipine Monotherapy in Diabetic Hypertensive Patients: An 8-Week Randomized, Parallel-Group, Double-Blind Trial
Clinical Therapeutics 2012cited by 21position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Robert Weiss · Amgen (United States)2 papers (2014–2014) · 2 papers (2014–2014)Jonathan Fialkow · Houston Methodist2 papers (2014–2014)Jason C. Legg · US Biologic (United States)2 papers (2014–2014)Patric Nelson · Amgen (United States)2 papers (2014–2014)Ransi Somaratne · University of Alabama at Birmingham2 papers (2014–2014)William J. Rogers · Universidad Nacional del Centro de la Provincia de Buenos Aires2 papers (2014–2014)Ludwin Ley · New York University2 papers (2012–2012)Robert C. Scott · Japan Real Estate Institute2 papers (2014–2014)Scott M. Wasserman · Amgen (United States)2 papers (2014–2014)Jennifer G. Robinson · St George's Hospital2 papers (2014–2014) · 2 papers (2014–2014) · 1 papers (2012–2012)Arya M. Sharma · York University1 papers (2012–2012) · 1 papers (2022–2022)George L. Bakris · University of Mississippi1 papers (2012–2012)Björn Dahlöf · New York University1 papers (2012–2012) · 1 papers (2022–2022) · 1 papers (2012–2012)Richard Vinisko · Boehringer Ingelheim (Brazil)1 papers (2012–2012)